neovaginal symptoms (discharge) in transgender women Microbiota, Microbiome, Neovagina, Sexual reassignment surgery, Transgender woman, Transwoman, Transfeminine, Lactobacillus, Penile inversion
Conditions
Interventions
estriol 0.03mg plus lactobacilli 100 million viable call vaginal route for 12 days
pre-post treatment compare
Experimental Drug
estriol and lactobacilli vaginal tablet
Sponsors
Ratchadapiseksompotch fund
Eligibility
Sex/Gender
Male
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Transgender woman who undergone vaginoplasty more than 6 months (inverted penile skin flap technique) 2. Have vaginal symptom (discharge) 3. Can communicate in Thai
Exclusion criteria
Exclusion criteria: 1. Infected abnormal discharge (fungi, parasite) 2. Vaginal douche within 3 days 3. Sexual intercourse via neovaginal route within 3 days 4. Antibiotic used within 4 weeks 5. Medical drug use via neovagina within 4 weeks 6. Active complication from surgery or last treatment within 6 months 7. Unable to follow up 8. Medical condition (DM, autoimmune disease, HIV, cancer)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| neovaginal discharge at the day after end of the intervention visual analog scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Neovaginal microbiome species at the day after end of the intervention 16S rDNA Next Generation Sequencing | — |
Countries
Thailand
Contacts
Public ContactSwita Luengyosluechakul
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed